- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 69
- States / cities
- Phoenix, Arizona • Springdale, Arkansas • Arcadia, California + 61 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Macular Degeneration, Wet Macular Degeneration
- Interventions
- Intravitreal aflibercept injection
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Cystoid Macular Edema, Diabetic Macular Edema
- Interventions
- Intravitreal Aflibercept Injection
- Drug
- Lead sponsor
- California Retina Consultants
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 2
- States / cities
- Bakersfield, California • Santa Barbara, California
- Conditions
- Wet Macular Degeneration
- Interventions
- Aflibercept Ophthalmic, optovue angiovue
- Drug · Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- Intravitreal Aflibercept Injection 2mg
- Drug
- Lead sponsor
- Tennessee Retina
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetic Macular Edema
- Interventions
- MYL-1701P, Eylea
- Drug
- Lead sponsor
- Mylan Pharmaceuticals Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Sacramento, California • St. Petersburg, Florida + 9 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Iluvien 0.19 MG Drug Implant, Aflibercept
- Drug
- Lead sponsor
- Alimera Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 40
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 36 more
- Conditions
- Diabetic Macular Edema
- Interventions
- Prompt Laser, Prompt aflibercept, Deferred laser, Deferred aflibercept
- Procedure · Drug
- Lead sponsor
- Jaeb Center for Health Research
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 702 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 100
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 84 more
- Conditions
- Branch Retinal Vein Occlusion
- Interventions
- Macular Laser Photocoagulation, Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)
- Procedure · Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 45
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 42 more
- Conditions
- Macular Neovascularization Secondary to Age-Related Macular Degeneration
- Interventions
- 4D-150 IVT (3E10 vg/eye), EYLEA® (aflibercept) Injection 2 mg (0.05mL)
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 91
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona • Springdale, Arkansas + 79 more
- Conditions
- Age-related Wet Macular Degeneration
- Interventions
- CG-P5 peptide, Placebo, Aflibercept Injection [Eylea]
- Drug
- Lead sponsor
- Caregen Co. Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 7
- States / cities
- Manchester, Connecticut • Deerfield Beach, Florida • Augusta, Georgia + 4 more
- Conditions
- Neovascular (Wet) Age-Related Macular Degeneration
- Interventions
- 4D-150 IVT, Aflibercept IVT
- Biological
- Lead sponsor
- 4D Molecular Therapeutics
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 215 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2031
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Oxnard, California • Sacramento, California + 21 more
- Conditions
- Proliferative Diabetic Retinopathy
- Interventions
- Aflibercept, Endolaserless Vitrectomy
- Drug · Procedure
- Lead sponsor
- Southeast Retina Center, Georgia
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Augusta, Georgia
- Conditions
- Neovascular Age-related Macular Degeneration
- Interventions
- 0.5 mg Conbercept Intravitreal Injection, 1.0 mg Conbercept Intravitreal Injection, 2.0 mg Aflibercept Intravitreal Injection
- Biological
- Lead sponsor
- Chengdu Kanghong Biotech Co., Ltd.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 1,157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 63
- States / cities
- Phoenix, Arizona • Tucson, Arizona • Beverly Hills, California + 52 more
- Conditions
- Retinal Vein Occlusion
- Interventions
- Aflibercept
- Drug
- Lead sponsor
- Tennessee Retina
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 1
- States / cities
- Nashville, Tennessee
- Conditions
- Diabetic Macular Edema
- Interventions
- Ranibizumab 0.3 mg, Aflibercept 2.0 mg
- Drug
- Lead sponsor
- Arshad Khanani
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015 – 2017
- U.S. locations
- 1
- States / cities
- Reno, Nevada
- Conditions
- Diabetic Macular Edema
- Interventions
- Aflibercept Injection [Eylea]
- Drug
- Lead sponsor
- Advanced Eye Research Associates
- Industry
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2022
- U.S. locations
- 1
- States / cities
- South Dartmouth, Massachusetts
- Conditions
- Diabetic Macular Edema
- Interventions
- Intravitreal Aflibercept
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Wet Age Related Macular Degeneration, wAMD
- Interventions
- EYP-1901, Aflibercept (2.0 mg)
- Drug
- Lead sponsor
- EyePoint Pharmaceuticals, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 78
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 69 more
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- KHK4951, Aflibercept Injection
- Drug
- Lead sponsor
- Kyowa Kirin Co., Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 40
- States / cities
- Mesa, Arizona • Tucson, Arizona • Arcadia, California + 36 more
- Conditions
- Macular Edema, Retinal Vein Occlusion
- Interventions
- 4 mg CLS-TA, Sham, IVT aflibercept
- Drug
- Lead sponsor
- Clearside Biomedical, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 14
- States / cities
- Phoenix, Arizona • Beverly Hills, California • San Diego, California + 11 more
- Conditions
- Age-related Macular Degeneration (AMD)
- Interventions
- Aflibercept, Ranibizumab, Bevacizumab
- Other
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 369,600 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey
- Conditions
- Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema
- Interventions
- REGN910-3, REGN910, Intravitreal Aflibercept Injection (IAI)
- Drug
- Lead sponsor
- Regeneron Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 5
- States / cities
- Beverly Hills, California • Winter Haven, Florida • Boston, Massachusetts + 2 more
- Conditions
- Age Related Macular Degeneration
- Interventions
- aflibercept 2.0 mg
- Drug
- Lead sponsor
- David M. Brown, M.D.
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas